Biological Age Tests: What Do Longevity Studies Reveal?

What did the new longevity analysis find?

Published in Nature Medicine on August 21, the TranslAGE analysis applied common measurements to existing intervention datasets. Some medications produced larger average changes, while dietary interventions showed more consistent patterns across biomarkers. These comparisons assess biological signals; they do not establish which intervention extends life most effectively. [TranslAGE analysis](https://www.nature.com/articles/s41591-026-04562-9)

The authors also found that participants' health and study duration influenced responsiveness. Measurements designed around mortality risk or aging pace generally responded more strongly than clocks estimating chronological age. This could help researchers select measurements for future trials. [Study findings](https://www.nature.com/articles/s41591-026-04562-9)

Does a younger biological age mean you will live longer?

Epigenetic clocks analyze patterns of chemical marks on DNA. They estimate aspects of aging through statistical models, and different models can capture different signals. Research summarized by the National Institute on Aging links some estimates to chronic disease, cognitive difficulties, functional limitations and mortality. However, conventional information—including health behaviors and social circumstances—can predict outcomes as well as, or better than, these tests. [National Institute on Aging](https://www.nia.nih.gov/news/age-estimated-changes-dna-can-help-predict-health-outcomes-mortality-older-adults)

Predicting risk and proving treatment benefit require different evidence. The FDA explains that a biomarker can replace a clinical outcome only with appropriate supporting evidence. For example, researchers must establish that changing the measurement reliably predicts a meaningful benefit. Applied to longevity research, the implication is that improved clock scores need to be connected to outcomes such as preserved function or longer survival. Even an informative biomarker may miss adverse effects elsewhere in the body. [FDA explanation of biomarkers and surrogate endpoints](https://www.fda.gov/about-fda/innovation-fda/fda-facts-biomarkers-and-surrogate-endpoints)

Should biological-age results guide medication or supplement choices?

A practical implication of the evidence is that treatment decisions should focus on demonstrated benefits, relevant health conditions and potential harms. A favorable laboratory signal cannot establish the overall balance of benefit and risk. Before paying for an intervention advertised as reversing biological age, look for controlled human evidence showing improvements that patients can experience—not simply movement in a test score. [FDA guidance on interpreting surrogate measurements](https://www.fda.gov/about-fda/innovation-fda/fda-facts-biomarkers-and-surrogate-endpoints)

Medication review matters particularly for older adults, who may take several products for different conditions. The National Institute on Aging advises discussing new prescriptions, over-the-counter medicines and supplements with a healthcare professional and sharing a complete list of existing products. Supplements can address particular nutritional needs, but that purpose should be distinguished from an unsupported promise of rejuvenation. [NIA medication advice](https://www.nia.nih.gov/health/medicines-and-medication-management/taking-medicines-safely-you-age), [NIA vitamin and supplement information](https://www.nia.nih.gov/health/vitamins-and-supplements)